Moody Aldrich Partners LLC Purchases Shares of 38,371 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Moody Aldrich Partners LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 38,371 shares of the medical equipment provider's stock, valued at approximately $4,211,000. Moody Aldrich Partners LLC owned approximately 0.06% of Lantheus as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock worth $458,271,000 after buying an additional 389,828 shares in the last quarter. Farallon Capital Management LLC grew its stake in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after acquiring an additional 796,000 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after acquiring an additional 394,837 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after purchasing an additional 19,071 shares in the last quarter. Finally, Swedbank AB lifted its stake in Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock worth $79,266,000 after purchasing an additional 125,843 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Trading Down 0.8 %

Shares of LNTH stock traded down $0.83 during trading hours on Thursday, hitting $109.81. The company had a trading volume of 380,342 shares, compared to its average volume of 964,841. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The company's fifty day moving average is $107.02 and its 200 day moving average is $92.35. The stock has a market capitalization of $7.61 billion, a PE ratio of 16.76 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company's quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.40 earnings per share. Research analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company's stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the sale, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,981 shares of company stock valued at $2,689,156 in the last three months. 1.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on LNTH shares. Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Leerink Partners lifted their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price on the stock. Finally, B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.